Increased risk of diabetes mellitus and hyperlipidemia in patients with differentiated thyroid cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Hwa Young | - |
dc.contributor.author | Lee, Jooyoung | - |
dc.contributor.author | Kang, Jinmo | - |
dc.contributor.author | Lee, Eun Kyung | - |
dc.date.accessioned | 2024-04-19T06:30:35Z | - |
dc.date.available | 2024-04-19T06:30:35Z | - |
dc.date.issued | 2024-03 | - |
dc.identifier.issn | 0804-4643 | - |
dc.identifier.issn | 1479-683X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/73338 | - |
dc.description.abstract | Objective This study aimed to assess the risk of cardiometabolic disease (CMD) in patients with differentiated thyroid cancer (DTC) using a population-based nationwide cohort in Korea.Design This was a population-based cohort study.Methods We selected 2649 patients with DTC and 7947 matched controls. The primary outcome was the composite of CMD including diabetes mellitus (DM), hypertension, hyperlipidemia, cerebrovascular disease, and ischemic heart disease. The secondary outcomes were each individual type of CMD, all-cause mortality, and CMD-specific mortality. The cause-specific hazard ratios (HRs) for each outcome were estimated based on cause-specific Cox proportional hazard regression models.Results Patients with DTC had an 11% higher risk of the primary composite outcome than controls (HR, 1.11; 95% confidence interval [CI], 1.04-1.19). The risks of DM (HR, 1.22; 95% CI, 1.08-1.38) and hyperlipidemia (HR, 1.36; 95% CI, 1.24-1.48) were higher in patients with DTC. In contrast, the risk of CMD-specific mortality was lower in those with DTC (HR, 0.24; 95% CI, 0.09-0.68). A nonlinear, U-shaped relationship was observed between the daily dose of levothyroxine and the risk of DM (P = .021), but the risk of hyperlipidemia was low with high doses of levothyroxine in patients with DTC (P = .003).Conclusions Patients with DTC had an increased risk of CMD, especially DM and hyperlipidemia, but a low risk of CMD mortality. Special attention to metabolic diseases is required in the long-term follow-up of patients with DTC. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.title | Increased risk of diabetes mellitus and hyperlipidemia in patients with differentiated thyroid cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1093/ejendo/lvae026 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF ENDOCRINOLOGY, v.190, no.3, pp 248 - 255 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 001191340900001 | - |
dc.identifier.scopusid | 2-s2.0-85189184537 | - |
dc.citation.endPage | 255 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 248 | - |
dc.citation.title | EUROPEAN JOURNAL OF ENDOCRINOLOGY | - |
dc.citation.volume | 190 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | diabetes mellitus | - |
dc.subject.keywordAuthor | hyperlipidemia | - |
dc.subject.keywordAuthor | cardiovascular disease | - |
dc.subject.keywordAuthor | cerebrovascular disease | - |
dc.subject.keywordAuthor | differentiated thyroid cancer | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | DISEASES | - |
dc.subject.keywordPlus | HORMONE | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.